Clinical Trials Arena on MSN

Teva and Sanofi’s TL1A mAb shows durability in UC and CD

In the Phase IIb trial, the drug was still benefiting patients after 58 weeks of treatment.

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well ...
Verywell Health

9 Probiotic Drinks That Support a Healthier Gut

Probiotic drinks contain live microorganisms that can affect gut health, digestion, and the balance of bacteria in the digestive system. They come in various formulations including water, sodas, kefir ...